Targeted therapies: New standard of therapy for HER2-positive gastric cancers?
- PMID: 21049571
- DOI: 10.1038/nrclinonc.2010.161
Targeted therapies: New standard of therapy for HER2-positive gastric cancers?
Comment on
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
Similar articles
-
Recent advances in the HER2 targeted therapy of gastric cancer.World J Clin Cases. 2015 Jan 16;3(1):42-51. doi: 10.12998/wjcc.v3.i1.42. World J Clin Cases. 2015. PMID: 25610849 Free PMC article. Review.
-
Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.J Clin Gastroenterol. 2012 Sep;46(8):637-48. doi: 10.1097/MCG.0b013e3182557307. J Clin Gastroenterol. 2012. PMID: 22751336 Review.
-
Human epidermal growth factor receptor 2-positive digestive tumors.Curr Opin Oncol. 2019 Jul;31(4):354-361. doi: 10.1097/CCO.0000000000000544. Curr Opin Oncol. 2019. PMID: 31170116 Review.
-
The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond.J Gastrointest Oncol. 2016 Oct;7(5):750-762. doi: 10.21037/jgo.2016.06.10. J Gastrointest Oncol. 2016. PMID: 27747089 Free PMC article. Review.
-
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.Clin Cancer Res. 2019 Apr 1;25(7):2033-2041. doi: 10.1158/1078-0432.CCR-18-2275. Epub 2018 Nov 15. Clin Cancer Res. 2019. PMID: 30442682 Free PMC article. Review.
References
-
- Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous